

April 19, 2023



# Ensysce CEO Dr. Lynn Kirkpatrick To Present Featured Case Study of MPAR Overdose Protection Platform Accelerated Development

*~ Global QUOTIENT LIFE SCIENCES Webinar Today, April 19, 2023 at 11:30am ET ~*

**SAN DIEGO, CA / ACCESSWIRE / April 19, 2023** /Ensysce Biosciences, Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC), a clinical-stage company applying transformative chemistry to improve prescription drug safety, today announced the Company's CEO, Dr. Lynn Kirkpatrick will be participating in 'Strategies for Achieving Regulatory Milestones Faster: An Ensysce Biosciences & Quotient Sciences Customer Case Study Demonstrating the Benefits of an Integrated Approach for Accelerating Development' today, April 19 2023, at 11:30am ET as a featured speaker.

Ensysce Biosciences' PF614-MPAR is a novel opioid combination product for the potential treatment of chronic pain that is designed to prevent both abuse and overdose. It is currently in clinical trials using Quotient Sciences integrated formulation, manufacturing and Phase I clinical units.

Dr. Kirkpatrick will speak about how MPAR may impact future pain treatment or other target diseases and will highlight the reasons Ensysce selected Quotient Sciences as their development partner.

## **Strategies for Achieving Regulatory Milestones Faster | Global Webinar**

Date: Wednesday, April 19, 2023

Time: 11:30 am ET

Register [here](#)

## **About Ensysce Biosciences**

Ensysce Biosciences is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. Leveraging TAAP™ and MPAR™, the Company is in the process of developing a unique, tamper-proof treatment option for pain that minimizes the risk of both drug abuse and overdoses. Ensysce's products are anticipated to provide safer options to treat patients suffering from severe pain and assist in preventing deaths caused by medication abuse. The platforms are covered by an extensive worldwide intellectual property portfolio for a wide array of prescription drug compositions. For more information, please visit [www.ensysce.com](http://www.ensysce.com).

## Forward-Looking Statements

Statements contained in this press release that are not purely historical may be deemed to be forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995 and other federal securities laws. Without limiting the foregoing, the use of words such as "may," "intends," "can," "might," "will," "expect," "plan," "possible," "believe" and other similar expressions are intended to identify forward-looking statements. The product candidates discussed are in clinic and not approved and there can be no assurance that the clinical programs will be successful in demonstrating safety and/or efficacy, that Ensysce will not encounter problems or delays in clinical development, or that any product candidate will ever receive regulatory approval or be successfully commercialized. All forward-looking statements are based on estimates and assumptions by Ensysce's management that, although Ensysce believes to be reasonable, are inherently uncertain. All forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those that Ensysce expected. In addition, Ensysce's business is subject to additional risks and uncertainties, including among others, the initiation and conduct of preclinical studies and clinical trials; the timing and availability of data from preclinical studies and clinical trials; expectations for regulatory submissions and approvals; potential safety concerns related to, or efficacy of, Ensysce's product candidates; the availability or commercial potential of product candidates; the ability of Ensysce to fund its continued operations, including its planned clinical trials; the dilutive effect of stock issuances from our fundraising; and Ensysce's and its partners' ability to perform under their license, collaboration and manufacturing arrangements. These statements are also subject to a number of material risks and uncertainties that are described in Ensysce's most recent quarterly report on Form 10-Q and current reports on Form 8-K, which are available, free of charge, at the SEC's website at [www.sec.gov](http://www.sec.gov). Any forward-looking statement speaks only as of the date on which it was made. Ensysce undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required under applicable law.

### Ensysce Biosciences Company Contact

Lynn Kirkpatrick, Ph.D.  
Chief Executive Officer  
(858) 263-4196

### Ensysce Biosciences Investor Relations Contact:

MZ Group North America  
Shannon Devine  
203-741-8811  
[ENSC@mzgroup.us](mailto:ENSC@mzgroup.us)

**SOURCE:** Ensysce Biosciences Inc.

View source version on accesswire.com:

<https://www.accesswire.com/750118/Ensysce-CEO-Dr-Lynn-Kirkpatrick-To-Present-Featured-Case-Study-of-MPAR-Overdose-Protection-Platform-Accelerated-Development>

